Crossmark

Insufficient persistence to pharmacotherapy in Japanese patients with osteoporosis: an analysis of the National Database of Health Insurance Claims and Specific Health Checkups in Japan

Crossref DOI link: https://doi.org/10.1007/s11657-021-00993-8

Published Online: 2021-09-13

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nakatoh, Shinichi

Fujimori, Kenji

Ishii, Shigeyuki

Tamaki, Junko

Okimoto, Nobukazu

Ogawa, Sumito

Iki, Masayuki
License Information

Text and Data Mining valid from 2021-09-13

Version of Record valid from 2021-09-13
More Information

Article History

Received: 10 March 2021

Accepted: 20 July 2021

First Online: 13 September 2021

Declarations

:

: The study was conducted according to the principles of the Declaration of Helsinki and was approved by the Ethics Committee of Kindai University Faculty of Medicine (approval number: 31–065).

: S. Nakatoh received payments for lectures, including speakers’ bureau fees, from Asahi-Kasei Pharmaceutical Co., Ltd.; Pfizer Japan Inc.; Ltd.; Amgen K.K.; Astellas Pharma Inc.; and Teijin Pharma Ltd. N. Okimoto received consulting fees from Asahi-Kasei Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. N. O received payments for lectures, including speakers’ bureau fees, from Asahi-Kasei Pharmaceutical Co., Ltd.; Amgen Astellas BioPharma K.K.; Astellas Pharma Inc.; Chugai Pharmaceutical Co.; Daiichi-Sankyo Co. Ltd.; Eisai Co., Ltd.; Eli Lilly Japan.; and Teijin Pharma Ltd. The other authors have no conflict of interest.

: The data in this study were completely anonymous. All data used in our analysis were de-identified by the Ministry of Health, Labour and Welfare, and this study followed the guidelines of the Ministry of Information Security. Thus, informed consent was not required.

Document is current

Any future updates will be listed below